GBIO Stock Price, Generation Bio Co Quote, Chart

Market Summary

USD3.12-0.58

Market Closed

-15.68%

GBIO Stock Price

View Fullscreen

GBIO RSI Chart

GBIO Valuation

Market Cap

247.3M

Price/Earnings (Trailing)

-1.95

Price/Sales (Trailing)

41.89

Price/Free Cashflow

-4.11

GBIO Price/Sales (Trailing)

GBIO Profitability

Return on Equity

-62.33%

Return on Assets

-33.79%

Free Cashflow Yield

-24.32%

GBIO Fundamentals

GBIO Revenue

Revenue (TTM)

5.9M

Rev. Growth (Qtr)

34.11%

GBIO Earnings

Earnings (TTM)

-126.6M

Earnings Growth (Yr)

-8.58%

Earnings Growth (Qtr)

-24.48%

Breaking Down GBIO Revenue

Last 7 days

-14.5%

Last 30 days

20.4%

Last 90 days

106.7%

Trailing 12 Months

-17.3%

How does GBIO drawdown profile look like?

GBIO Financial Health

Current Ratio

6.83

GBIO Investor Care

Shares Dilution (1Y)

11.42%

Diluted EPS (TTM)

-1.96

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	5.9M
2022	0	0	0	0
2021	0	0	0	0
2018	0	0	0	36.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Generation Bio Co

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 29, 2024	kerr douglas	acquired	-	-	5,021	chief medical officer
Jan 29, 2024	zimmermann tracy	acquired	-	-	5,021	chief development officer
Jan 29, 2024	zimmermann tracy	sold (taxes)	-2,804	1.9	-1,476	chief development officer
Jan 29, 2024	kerr douglas	sold (taxes)	-2,804	1.9	-1,476	chief medical officer
Jan 15, 2024	paone antoinette	sold (taxes)	-6,946	1.91	-3,637	chief operating officer
Jan 15, 2024	stanton matthew	acquired	-	-	14,131	chief scientific officer
Jan 15, 2024	samayoa phillip	sold (taxes)	-5,768	1.91	-3,020	chief strategy officer
Jan 15, 2024	samayoa phillip	acquired	-	-	8,712	chief strategy officer
Jan 15, 2024	kerr douglas	acquired	-	-	14,131	chief medical officer
Jan 15, 2024	stanton matthew	sold (taxes)	-9,353	1.91	-4,897	chief scientific officer

Which funds bought or sold GBIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	added	38.37	1,098,230	1,553,360	-%
Apr 05, 2024	GAMMA Investing LLC	unchanged	-	173	322	-%
Mar 11, 2024	VANGUARD GROUP INC	added	9.13	-4,652,780	4,211,210	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	235	1,209,490	3,826,370	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.41	-48,516	37,138	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	reduced	-7.09	-16,825,000	11,429,000	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	added	207	55,000	215,000	0.02%
Feb 15, 2024	Legal & General Group Plc	unchanged	-	-8,406	6,447	-%
Feb 15, 2024	BARCLAYS PLC	added	399	60,000	112,000	-%

Are Funds Buying or Selling GBIO?

Are funds buying GBIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GBIO

No. of Funds

Unveiling Generation Bio Co's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	price t rowe associates inc /md/	10.5%	6,926,174	SC 13G/A
Feb 13, 2024	bb biotech ag	5.5%	3,608,280	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	atlas venture fund x, l.p.	10.8%	7,111,939	SC 13G/A
Jan 08, 2024	blackrock inc.	4.8%	3,168,415	SC 13G/A
Dec 11, 2023	fmr llc	-	0	SC 13G/A
Mar 24, 2023	modernatx, inc.	8.9%	5,859,375	SC 13G
Feb 14, 2023	t. rowe price investment management, inc.	6.0%	3,577,755	SC 13G
Feb 14, 2023	bb biotech ag	6.1%	3,608,280	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	12.2%	7,261,046	SC 13G/A

Recent SEC filings of Generation Bio Co

View All Filings

Date Filed	Form Type	Document
Mar 06, 2024	10-K	Annual Report
Mar 06, 2024	8-K	Current Report
Mar 06, 2024	S-8	Employee Benefits Plan
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 09, 2024	SC 13G/A	Major Ownership Report
Feb 09, 2024	SC 13G/A	Major Ownership Report
Feb 02, 2024	8-K	Current Report
Jan 31, 2024	4	Insider Trading
Jan 31, 2024	4	Insider Trading

Peers (Alternatives to Generation Bio Co)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	0.01%	-33.89%	-8.42	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.06%	-27.57%	-42.25	10.17	76.23%	61.08%
BMRN	17.3B	2.4B	9.12%	-7.56%	103	7.14	15.42%	18.43%
INCY	12.0B	3.7B	-8.48%	-28.30%	20.07	3.25	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.27%	-36.41%	-11.74	15.65	425.83%	18.94%
BBIO	4.5B	-	-6.46%	74.90%	-6.94	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-9.62%	-0.34%	-13.52	11.95	440.80%	-27.84%
ARWR	3.0B	240.7M	-15.06%	-21.14%	-10.03	12.36	-1.03%	-92.09%
ACAD	2.8B	726.4M	-8.60%	-6.11%	-45.41	3.83	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.17%	-12.95%	25.42	4.56	85.90%	-14.05%
NVAX	576.6M	983.7M	-22.12%	-55.02%	-1.06	0.59	-50.36%	17.16%
CRBP	448.6M	881.7K	-2.13%	345.78%	-10.06	466.16	-77.61%	-5.33%
INO	256.8M	4.9M	2.33%	7.75%	-1.9	52.78	-54.97%	51.72%
IBIO	6.7M	2.1M	82.86%	81.13%	-0.25	2.14	-13.45%	66.37%

Generation Bio Co News

Latest updates

Generation Bio Co Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)										(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2018Q4
Revenue	34.1%	2,878	2,146	880	-	-	-	-	-	-	-
Operating Expenses	23.3%	41,299	33,503	34,799	34,866	34,688	32,669	38,481	35,344	30,946	-
S&GA Expenses	14.9%	13,376	11,641	12,967	12,866	13,081	11,477	10,116	9,790	9,099	-
R&D Expenses	27.7%	27,923	21,862	21,832	22,000	21,607	21,192	28,365	25,554	21,847	-
Net Income	-24.5%	-35,186	-28,266	-31,066	-32,094	-32,405	-31,306	-37,929	-34,999	-30,924	-
Net Income Margin	-Infinity%	-21.45*	-	-	-	-	-	-	-	-2.29	-
Free Cashflow	-15.9%	-29,558	-25,506	23,354	-28,432	-23,685	-21,128	-28,217	-38,219	-23,637	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	-1.8%	375	381	405	431	376	403	419	444	477	464	491	514	294	311	331	187	42.00	84.00
Current Assets	-8.5%	273	298	321	345	287	311	321	342	379	403	433	456	268	286	306	-	18.00	77.00
Cash Equivalents	-22.6%	72.00	93.00	145	96.00	93.00	140	164	343	381	394	394	368	65.00	61.00	174	107	17.00	9.00
Net PPE	15.3%	26.00	22.00	22.00	22.00	22.00	23.00	25.00	28.00	26.00	23.00	24.00	23.00	24.00	23.00	23.00	-	22.00	4.00
Liabilities	14.7%	172	150	151	152	94.00	94.00	94.00	91.00	95.00	57.00	57.00	55.00	26.00	24.00	27.00	26.00	25.00	10.00
Current Liabilities	21.6%	40.00	33.00	26.00	23.00	19.00	17.00	16.00	15.00	19.00	15.00	14.00	11.00	11.00	9.00	12.00	-	9.00	7.00
Shareholder's Equity	-12.4%	203	232	254	279	282	309	325	353	382	407	433	459	268	287	304	-	-	-
Retained Earnings	-6.6%	-571	-536	-507	-476	-444	-412	-381	-343	-308	-277	-245	-214	-188	-164	-143	-	-108	-47.13
Additional Paid-In Capital	0.8%	774	768	762	756	727	721	706	696	690	684	679	673	457	451	448	-	10.00	6.00
Shares Outstanding	0.4%	66.00	66.00	66.00	66.00	60.00	59.00	57.00	57.00	57.00	56.00	56.00	55.00	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Cashflow From Operations	-0.3%	-24,978	-24,896	24,806	-27,677	-23,003	-20,477	-23,533	-35,435	-20,802	-22,555	-25,437	-23,027	-18,365	-18,513	-15,484	-17,780	-11,807	-11,783	-	-
Share Based Compensation	0.7%	6,048	6,004	6,023	6,266	5,847	5,848	6,691	6,066	4,735	4,970	4,970	3,479	3,379	2,161	1,368	1,504	1,085	1,080	1,049	-
Cashflow From Investing	92.8%	-1,914	-26,583	24,415	-5,616	-18,396	-12,614	-158,721	-2,784	7,165	22,165	50,232	113,485	20,351	-93,925	-129,611	-2,011	4,922	3,375	-	-
Cashflow From Financing	158.8%	77.00	-131	99.00	35,772	83.00	9,313	3,541	52.00	435	306	973	212,957	2,297	-648	212,313	109,133	69.00	-	-	-

GBIO Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Collaboration revenue	$ 5,904	$ 0	$ 0
Operating expenses:
Research and development	93,617	96,718	85,247
General and administrative	50,850	44,464	33,854
Total operating expenses	144,467	141,182	119,101
Loss from operations	(138,563)	(141,182)	(119,101)
Other income:
Other income (expense) and interest income, net	11,951	4,543	(50)
Net loss	$ (126,612)	$ (136,639)	$ (119,151)
Net loss per share, basic	$ (1.96)	$ (2.35)	$ (2.12)
Net loss per share, diluted	$ (1.96)	$ (2.35)	$ (2.12)
Weighted average common shares outstanding, basic	64,483,520	58,114,893	56,295,409
Weighted average common shares outstanding, diluted	64,483,520	58,114,893	56,295,409
Comprehensive loss:
Net loss	$ (126,612)	$ (136,639)	$ (119,151)
Other comprehensive loss:
Unrealized gains (losses) on marketable securities	357	(83)	(9)
Comprehensive loss	$ (126,255)	$ (136,722)	$ (119,160)

GBIO Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 66,446	$ 93,171
Marketable securities	197,918	185,920
Tenant receivable	3,960	395
Prepaid expenses and other current assets	4,294	7,530
Total current assets	272,618	287,016
Property and equipment, net	25,799	22,215
Operating lease right-of-use assets	69,852	59,208
Restricted cash	5,791	5,692
Deferred offering costs	433	434
Other long-term assets	265	1,699
Total assets	374,758	376,264
Current liabilities:
Accounts payable	2,346	662
Accrued expenses and other current liabilities	16,529	11,402
Deferred revenue	12,919	0
Operating lease liability	8,120	7,086
Total current liabilities	39,914	19,150
Deferred revenue, net of current portion	41,942	0
Operating lease liability, net of current portion	89,774	74,621
Total liabilities	171,630	93,771
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at December 31, 2023 and December 31, 2022	0	0
Common stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2023 and December 31, 2022; 66,205,550 and 59,505,437 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	7	6
Additional paid-in capital	774,224	727,335
Accumulated other comprehensive income (loss)	274	(83)
Accumulated deficit	(571,377)	(444,765)
Total stockholders' equity	203,128	282,493
Total liabilities and stockholders' equity	$ 374,758	$ 376,264

About Generation Bio Co

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Cameron Geoffrey McDonough M.D.
WEBSITE	https://generationbio.com
INDUSTRY	Biotechnology
EMPLOYEES	150

Generation Bio Co Frequently Asked Questions

What is the ticker symbol for Generation Bio Co? What does GBIO stand for in stocks?

GBIO is the stock ticker symbol of Generation Bio Co. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Generation Bio Co (GBIO)?

As of Mon Apr 15 2024, market cap of Generation Bio Co is 247.29 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GBIO stock?

You can check GBIO's fair value in chart for subscribers.

What is the fair value of GBIO stock?

You can check GBIO's fair value in chart for subscribers. The fair value of Generation Bio Co is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Generation Bio Co is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GBIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Generation Bio Co a good stock to buy?

The fair value guage provides a quick view whether GBIO is over valued or under valued. Whether Generation Bio Co is cheap or expensive depends on the assumptions which impact Generation Bio Co's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GBIO.

What is Generation Bio Co's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, GBIO's PE ratio (Price to Earnings) is -1.95 and Price to Sales (PS) ratio is 41.89. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GBIO PE ratio will change depending on the future growth rate expectations of investors.